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This retrospective  observational  medical  chart  review  aimed  to describe  country-speciﬁc  variations
across  Europe  in real-world  meticillin-resistant  Staphylococcus  aureus  (MRSA)  complicated  skin  and  soft-
tissue  infection  (cSSTI)  treatment  patterns,  antibiotic  stewardship  activity,  and  potential  opportunities
for  early  switch  (ES)  from  intravenous  (i.v.)  to oral  formulations  and  early  discharge  (ED)  from  hospital
using  standardised  data  collection  and  criteria  and  economic  implications  of  these  opportunities.  Patients
were  randomly  sampled  from  12 countries  (Austria,  Czech  Republic,  France,  Germany,  Greece,  Ireland,
Italy, Poland,  Portugal,  Slovakia,  Spain  and  the  UK),  aged  ≥18  years,  with  documented  MRSA  cSSTI,  hos-
pitalised  between  1 July  2010  and 30 June  2011,  discharged  alive  by  31  July  2011.  Of 1502  patients,
1468 received  MRSA-targeted  therapy.  Intravenous-to-oral  switch  rates  ranged  from  2.0%  to 20.2%,  i.v.
length  of  therapy  from  10.1  to 18.6  days  and  hospital  length  of  stay  (LoS)  from  15.2 to  25.0 days  across
Europe.  Of 341  sites,  82.9%  had  antibiotic  steering  committees,  23.7%  had  i.v.-to-oral  switch  antibiotic
protocols  and  12.9%  had  ED  protocols  for MRSA  cSSTI. ES and  ED  eligibility  ranged  from  12.0%  (Slovakia)
to  56.3%  (Greece)  and  from  10%  (Slovakia)  to 48.2%  (Portugal),  respectively.  Potential  cost  savings  per
ED-eligible  patient  ranged  from  D414 (Slovakia)  to  D2703  (France).  MRSA  cSSTI  treatment  patterns  var-
ied  widely  across  countries,  but further  reductions  in  i.v. therapy,  hospital  LoS  and  associated  costs  could
be  realised.  These  data  provide  insight  into  clinical  practice  patterns  across  diverse  European  healthcare
systems  and  identify  potential  opportunities  for local  clinicians  and  policy-makers  to improve  clinical
care  and  cost-effectiveness  of this  therapeutic  area.
©  2014  The  Authors.  Published  by  Elsevier  B.V.  on  behalf  of  International  Society of  Chemotherapy.
This  is an open  access  article  under  the  CC  BY-NC-SA  license∗ Corresponding author. Tel.: +1 240 821 1290.
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924-8579/© 2014 The Authors. Published by Elsevier B.V. on behalf of International Soci
http://creativecommons.org/licenses/by-nc-sa/3.0/).(http://creativecommons.org/licenses/by-nc-sa/3.0/).
1. IntroductionEuropean healthcare systems are under increasing economic
pressure, with greater demand to provide care despite stable or
declining budgets [1]. The percentage of patients aged ≥80 years
is projected to increase (4.4% in 2008, 8% in 2035, 12.1% in 2060),
ety of Chemotherapy. This is an open access article under the CC BY-NC-SA license
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hilst the number of hospital facilities and beds in Europe will
ikely decrease [2]. This underscores the need for programmes that
an enable hospitalised patients to continue treatment in outpa-
ient settings with few negative impacts.
Outpatient parenteral antibiotic therapy (OPAT) programmes
nable patients to receive intravenous (i.v.) antibiotics after hospi-
al discharge but require additional resources and are not available
o all patients in Europe [3–5]. Early switch (ES) programmes
romote switching patients from i.v.-to-oral antibiotic therapies,
nd early discharge (ED) programmes enable patients to ﬁnish
reatment after hospital discharge. ES and ED programmes are
eneﬁcial [6–10], require few additional resources and are consid-
red relatively low cost and high impact antimicrobial stewardship
trategies [11]. These programmes are regarded as having the great-
st potential beneﬁt for the management of meticillin-resistant
taphylococcus aureus (MRSA) infections, particularly complicated
kin and skin-structure infections [7,12]. Clinical trial data in MRSA
omplicated skin and soft-tissue infection (cSSTI) have suggested
onger length of stay (LoS) in Europe compared with other world
egions owing to different healthcare systems and incentives [13].
Variations have been reported in ambulatory use of antibi-
tics and hospitalised respiratory infections [6,7]; however, little
s known about variations in real-world MRSA cSSTI treatment
atterns in hospitals across different European countries. Given
imited pan-European data on real-world practice patterns for
reatment of MRSA cSSTI as well as expected economic pressures
o optimise available resource use, a retrospective observational
tudy was conducted using consistent methodology across 12 Euro-
ean countries. The objectives were: (i) to illustrate cross-country
ariations in practice patterns for MRSA cSSTI treatment, including
nitiation of therapy, choice of drugs, treatment regimen changes,
nd duration of therapy and hospitalisation; (ii) to assess current
vailability and impact of hospital antibiotic drug use policies; (iii)
o describe potential opportunities for ES and ED by application of
tandardised criteria across countries; and (iv) to demonstrate the
otential economic impact of ES and ED programmes at the country
evel. These data may  provide insight into clinical practice patterns
cross diverse European healthcare systems and may  help identify
pportunities to improve the efﬁciency of patient care.
. Methods
A retrospective observational medical chart review was con-
ucted including 12 European countries: Austria, Czech Republic,
rance, Germany, Greece, Ireland, Italy, Poland, Portugal, Slovakia,
pain, and the UK. The complete methods will be published in a
orthcoming paper. Study investigators [hospital-based infectious
iseases (ID) specialists, internists with an ID subspecialty and
edical microbiologists] identiﬁed patients for data collection.
Included patients were: hospitalised between 1 July 2010 and
0 June 2011 inclusive and were discharged alive by 31 July
011; were aged ≥18 years; had a conﬁrmed MRSA cSSTI (e.g.
eep/extensive cellulitis, infected wound or ulcer, major abscess
r other soft-tissue infection requiring substantial surgical inter-
ention); and received ≥3 days of i.v. anti-MRSA antibiotics.
atients were excluded if they: were treated for the same SSTI ≤3
onths from hospitalisation; had suspected or proven diabetic foot
nfection, osteomyelitis, infective endocarditis, meningitis, joint
nfection, necrotising fasciitis, gangrene, prosthetic joint infection
r prosthetic implant/device infection; were pregnant or lactating;
ad signiﬁcant concomitant infection at other sites (e.g. bacter-
emia, pneumonia); were immunosuppressed (e.g. diagnosed with
aematological malignancy or rheumatoid arthritis, neutropenic,
ndergoing cancer chemotherapy, receiving chronic steroids); or
ere enrolled in another cSSTI-related clinical trial.ntimicrobial Agents 44 (2014) 56–64 57
2.1. Study populations
The main study population included patients whose med-
ical charts were randomly selected by study investigators so
that the population accurately reﬂected practice patterns of each
country. A limited number of patients received treatment with
questionable or suboptimal coverage for MRSA. Thus, a subgroup
was identiﬁed who received a conﬁrmed MRSA-active antibi-
otic with a labelled or guideline indication for MRSA cSSTI or
with anti-MRSA activity conﬁrmed by susceptibility tests [e.g. i.v.
chloramphenicol, i.v./oral clindamycin, i.v. daptomycin, i.v./oral
doxycycline, i.v. fosfomycin, i.v./oral fusidic acid, i.v. lincomycin,
i.v./oral linezolid, oral minocycline, i.v. netilmicin, i.v. norﬂoxacin,
i.v. quinupristin/dalfopristin, i.v./oral rifampicin, i.v./oral trimetho-
prim/sulfamethoxazole, i.v. teicoplanin, i.v. tigecycline, oral
trimethoprim and i.v. vancomycin]. The following antibiotics were
considered MRSA-active after reviewing wound cultures for MRSA
sensitivity: i.v./oral ciproﬂoxacin; i.v. ertapenem; i.v. imipenem;
i.v./oral levoﬂoxacin; i.v. meropenem; i.v./oral moxiﬂoxacin; and
oral oﬂoxacin. Owing to limited recruitment, patients from Ireland
contributed to the overall cohort but their results are not presented
separately.
2.2. Key outcomes
2.2.1. Hospital-level organisation and protocols for antibiotic use
and early discharge
A separate hospital-level information form collected site data on
the presence of antibiotic subcommittees and drug use policies for
i.v.-to-oral antibiotic switching or ED. These data were summarised
by country to understand existing country-level systems at the time
of the study to address i.v.-to-oral antibiotic switching and ED.
2.2.2. Meticillin-resistant S. aureus-active antibiotic treatment
patterns
Patient-level ﬁrst and last MRSA-active therapies administered
in hospital as well as MRSA-active therapies prescribed at discharge
(including drug and administration pattern) were determined over-
all and by country. Administration patterns evaluated included
i.v. only, i.v.-to-oral antibiotic switch and discharge on antibiotics
(i.v./intramuscular or oral).
2.2.2.1. Actual length of intravenous therapy and hospital length of
stay. Length of i.v. therapy and LoS were determined overall and
for each country. Length of i.v. therapy was deﬁned as the time
between start of MRSA-active i.v. treatment and last date of inpa-
tient i.v. antibiotic use. LoS was  measured from hospital admission
for patients admitted for treatment of MRSA cSSTI, from the date
of cSSTI diagnosis (cSSTI index date).
2.2.2.2. Early switch and early discharge opportunities. To explore
possible resource utilisation reductions, potential for ES (sooner
than patients actually discontinued their MRSA-active i.v. antibi-
otics) and for ED (earlier than actual discharge date on oral
antibiotics or through an OPAT programme) were evaluated. ES
and ED criteria were developed through literature review [3–10]
and expert consensus opinion. ES eligibility required patients to
meet all of the following criteria before i.v. discontinuation: sta-
ble clinical infection; afebrile/temperature <38 ◦C for 24 h; white
blood cell count normalised or not <4 × 109/L or >12 × 109/L; no
unexplained tachycardia; systolic blood pressure ≥100 mmHg (for
OPAT); and oral ﬂuids/medications/diet tolerated with no gastroin-
testinal absorption problems. ED eligibility required meeting all of
the above criteria for ES before discharge and having no reason to
remain hospital except for infection management.
5 al of A
r
i
b
P
e
t
L
s
u
(
w
l
2
c
d

v
a
a
p
u
a
u
r
n
a
p
i
a
S
3
3
p
a
m
a
m
p
a
a
c
(
m
b
3
h
o
c
9
t
c
t
p8 C. Eckmann et al. / International Journ
To understand the impact ES and ED eligibility could have on
esource utilisation, potential i.v. days saved due to ES eligibil-
ty were calculated as excess days between the time the patient
ecame eligible and when they actually discontinued i.v. therapy.
otential bed-days saved due to ED eligibility were calculated as
xcess days between the time patients became eligible and when
hey were actually discharged. The potential economic beneﬁt of
oS reductions was calculated by multiplying potential bed-day
avings by country-speciﬁc World Health Organization-reported
nit costs (international dollars) for a hospital bed-day in 2008
Appendix) [14]. Unit costs were adjusted for inﬂation to 2012 and
ere converted to euros [15,16]. Costs were applied at a patient
evel (e.g. person-level bed-days saved × cost per bed-day).
.3. Statistical analysis
Categorical variables were summarised as frequencies and per-
entages and continuous variables as the mean and standard
eviation (S.D.). To test for differences between groups, Pearson’s
2 test for categorical variables and Student’s t-test or analysis of
ariance for continuous variables were used. For the analyses: (i)
ll patients in the main cohort were used to describe demographic
nd disease characteristics, ES and ED eligibilities, and actual hos-
ital LoS; (ii) the subset receiving MRSA-active treatment was
sed for MRSA-active antibiotic treatment patterns and i.v. ther-
py days; and (iii) the subsets who were eligible for ES or ED were
sed to describe the potential savings in i.v. days or hospital LoS,
espectively. At a country level, correlations and their statistical sig-
iﬁcances were evaluated between the proportion of sites having
n antibiotic subcommittee and i.v.-to-oral antibiotic switch or ED
rotocols and the proportion of patients observed to switch from
.v. to oral antibiotics, mean i.v. days and mean LoS. All inferences
ssumed a 2-sided test with an  ˛ of 0.05. Statistical analyses utilised
AS software v.9.2 (SAS Institute Inc., Cary, NC).
. Results
.1. Patient demographic and disease characteristics
In total, 1502 patients enrolled with a by-country range of 217
atients (Germany) to 2 patients (Ireland) (Table 1).
Most patients were white (92.9%), male (61.1%), with a mean
ge of 60.9 years at hospital admission and with at least 1 docu-
ented co-morbidity at hospital admission, with diabetes (31.3%)
nd peripheral vascular disease (23.8%) being the most com-
on. Moreover, 88.6% of patients were hospitalised with the
rimary reason of MRSA cSSTI treatment; ca. 50% were classiﬁed
s community-acquired infections, although this percentage varied
cross countries. The most common infection types were extensive
ellulitis (26.1%), surgical site infections or post-traumatic wounds
26.0%) and infected ulcers (24.7%). Surgical procedures for cSSTI
anagement (incision and drainage, debridement) were required
y 38.7% of patients.
.2. Study hospital characteristics
Study investigators (n = 341) were located primarily at urban
ospitals (91.2%; range 79.2–100% across countries) with a mean
f 738.4 beds (39.9 critical care beds). Hospital size varied across
ountries (mean range of 315.7 beds per hospital in Slovakia to
47.6 beds in the UK).
Sites reporting antibiotic subcommittees or steering commit-
ees or i.v.-to-oral antibiotic switch protocols varied greatly across
ountries (across all sites: 82.9% reported antibiotic subcommit-
ees or steering committees, 23.7% had i.v.-to-oral antibiotic switch
rotocols and 12.9% had ED protocols for MRSA cSSTI s) (Table 2).ntimicrobial Agents 44 (2014) 56–64
Cross-country comparisons showed a dynamic variability in the
presence of ED protocols for MRSA cSSTI [Czech Republic lowest
availability (0%); Spain highest (28.1%)].
Vancomycin (97.9%) and linezolid (93.5%) were the most com-
mon  MRSA-active therapies available on hospital formularies.
Restrictions on formulary (e.g. restricted to ID physicians, require-
ment for ID consult) were less frequent for vancomycin (14.4%)
than linezolid (38.2%). In cross-country comparisons, Italy had
the lowest percentage of formulary restrictions for vancomycin
(2.6%) and linezolid (20.5%). The highest frequencies of vancomycin
and linezolid formulary restrictions were in Greece (38.7%) and
the UK (57.4%), respectively. The most cited formulary restric-
tions were need for approval from medical/specialised committee
(vancomycin, 77.1%; linezolid, 68.0%), cost and insurance cover-
age (linezolid, 9.8%) and renal insufﬁciency (vancomycin, 14.6%).
Linezolid was the most frequently listed antibiotic on MRSA cSSTI
discharge protocols in all countries except Greece.
3.3. Patient-level meticillin-resistant S. aureus-active antibiotic
treatment patterns
Of the 1502 patients, 1468 (97.7%) received conﬁrmed MRSA-
targeted therapy; most patients (81.5%) received i.v. therapy only
(Table 3). Vancomycin was the most frequently used initial ther-
apy in all countries [from 23.1% (Austria) to 69.8% (Portugal)]; the
frequency of other antibiotics used varied across countries. Whilst
vancomycin was  still the most frequently used last therapy in all
countries except Slovakia (where 45.0% of patients used ﬂuoro-
quinolones), the proportion of patients using vancomycin dropped,
while rates of linezolid use remained the same or increased in all
countries compared with initial therapy.
In line with the cross-country variation in hospital antibiotic
protocols, a large degree of variation was found in observed antibi-
otic treatment patterns across Europe. Only 10.7% of patients were
switched from i.v. to oral antibiotic therapy while hospitalised
(range: Greece, 2.0% to Spain, 20.2%). Medium to large country-
level correlations were found between the proportion of sites
with antibiotic subcommittees (r = 0.66, P = 0.02), i.v.-to-oral antibi-
otic switch protocols (r = 0.42, P = 0.17) and ED protocols (r = 0.45,
P = 0.14) and rates of i.v.-to-oral antibiotic switch.
In total, 32.7% of patients were discharged from hospital
on MRSA-targeted therapies (range: Portugal, 18.0% to Greece,
49.7%). Most patients (92.7%) received oral MRSA-targeted thera-
pies upon discharge, with linezolid and clindamycin being the most
commonly prescribed. Patients discharged from hospital on oral
MRSA-targeted therapies received oral linezolid most frequently
in France (51.4%), Germany (49.0%), Portugal (52.0%) and Spain
(51.3%).
3.4. Actual length of intravenous therapy and hospital length of
stay
The number of MRSA-targeted i.v. days (P < 0.001) and mean
MRSA cSSTI hospital stay (P < 0.001) varied signiﬁcantly across
countries, with shortest i.v. days and LoS in the UK and longest
in Poland and Portugal, respectively (Fig. 1). There was weak to no
correlation between country-level mean i.v. days and proportion
of sites with antibiotic subcommittees (r = 0.08, P = 0.80), i.v.-to-
oral antibiotic switch protocols (r = 0.20, P = 0.54) or ED protocols
(r = −0.07). Country-level mean LoS had a moderate negative cor-
relation with the proportion of sites with antibiotic subcommittees
(r = −0.35, P = 0.26) but weak correlations with the proportion with
i.v.-to-oral antibiotic switch protocols (r = 0.03, P = 0.92) or ED pro-
tocols (r = 0.03, P = 0.93). Recurrence and re-admission due to MRSA
cSSTI within 30 days post discharge were both <1%.
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Table 1
Patient and disease characteristics.
All countries
(N = 1502)a
Austria
(n = 54)
Czech
Republic
(n = 41)
France
(n = 261)
Germany
(n = 217)
Greece
(n = 151)
Italy
(n = 190)
Poland
(n = 43)
Portugal
(n = 141)
Slovakia
(n = 50)
Spain
(n = 183)
UK
(n = 169)
Demographics
Mean (S.D.) age (years) 60.9 (16.5) 68.8 (13.1) 65.2 (16.6) 58.4 (16.5) 62.5 (14.8) 60.6 (17.6) 55.4 (15.3) 54.4 (15.1) 62.4 (14.9) 62.2 (15.0) 65.6 (17.4) 60.0 (18.2)
Male  [n (%)] 917 (61.1) 31 (57.4) 25 (61.0) 154 (59.0) 127 (58.5) 91 (60.3) 124 (65.3) 25 (58.1) 79 (56.0) 25 (50.0) 119 (65.0) 116 (68.6)
White  [n (%)] 1395 (92.9) 52 (96.3) 41 (100.0) 221 (84.7) 210 (96.8) 149 (98.7) 179 (94.2) 43 (100.0) 133 (94.3) 50 (100.0) 180 (98.4) 135 (79.9)
Race/ethnicity unknown/not documented 16 (1.1) 1 (1.9) 0 12 (4.6) 3 (1.4) 0 0 0 0 0 0 0
Co-morbidities at hospital admission [n (%)]b
None documented/reported 286 (19.0) 1 (1.9) 8 (19.5) 49 (18.8) 29 (13.4) 32 (21.2) 66 (34.7) 2 (4.7) 21 (14.9) 2 (4.0) 31 (16.9) 45 (26.6)
Reported co-morbidities 1216 (81.0) 53 (98.1) 33 (80.5) 212 (81.2) 188 (86.6) 119 (78.8) 124 (65.3) 41 (95.3) 120 (85.1) 48 (96.0) 152 (83.1) 124 (73.4)
Diabetes 470 (31.3) 18 (33.3) 20 (48.8) 74 (28.4) 92 (42.4) 38 (25.2) 33 (17.4) 6 (14.0) 50 (35.5) 20 (40.0) 69 (37.7) 50 (29.6)
PVD  358 (23.8) 17 (31.5) 21 (51.2) 48 (18.4) 63 (29.0) 33 (21.9) 17 (8.9) 13 (30.2) 47 (33.3) 25 (50.0) 49 (26.8) 25 (14.8)
CPD  285 (19.0) 11 (20.4) 6 (14.6) 52 (19.9) 47 (21.7) 24 (15.9) 23 (12.1) 17 (39.5) 22 (15.6) 6 (12.0) 47 (25.7) 30 (17.8)
CHF  283 (18.8) 15 (27.8) 9 (22.0) 24 (9.2) 88 (40.6) 24 (15.9) 5 (2.6) 4 (9.3) 40 (28.4) 11 (22.0) 37 (20.2) 25 (14.8)
CAD  (MI, CABG, etc.) 274 (18.2) 17 (31.5) 19 (46.3) 33 (12.6) 72 (33.2) 39 (25.8) 18 (9.5) 3 (7.0) 22 (15.6) 12 (24.0) 14 (7.7) 24 (14.2)
Renal  disease, moderate/severe 169 (11.3) 10 (18.5) 10 (24.4) 21 (8.0) 46 (21.2) 13 (8.6) 5 (2.6) 2 (4.7) 28 (19.9) 10 (20.0) 13 (7.1) 11 (6.5)
Liver  disease, mild 163 (10.9) 8 (14.8) 11 (26.8) 18 (6.9) 34 (15.7) 11 (7.3) 17 (8.9) 8 (18.6) 16 (11.3) 9 (18.0) 14 (7.7) 17 (10.1)
Infection characteristics [n (%)]
Type of cSSTI
Deep/extensive cellulitis 392 (26.1) 8 (14.8) 7 (17.1) 79 (30.3) 36 (16.6) 49 (32.5) 34 (17.9) 22 (51.2) 42 (29.8) 7 (14.0) 41 (22.4) 66 (39.1)
Surgical site infection or post-traumatic wound 390 (26.0) 11 (20.4) 15 (36.6) 57 (21.8) 60 (27.6) 39 (25.8) 58 (30.5) 7 (16.3) 41 (29.1) 27 (54.0) 44 (24.0) 31 (18.3)
Infected ulcer 371 (24.7) 24 (44.4) 11 (26.8) 50 (19.2) 57 (26.3) 30 (19.9) 48 (25.3) 4 (9.3) 38 (27.0) 4 (8.0) 70 (38.3) 35 (20.7)
Major  abscess 265 (17.6) 10 (18.5) 7 (17.1) 66 (25.3) 52 (24.0) 20 (13.2) 26 (13.7) 8 (18.6) 15 (10.6) 11 (22.0) 20 (10.9) 32 (18.9)
Other  (including infected burn) 84 (5.6) 1 (1.9) 1 (2.4) 12 (4.6) 12 (5.5) 13 (8.6) 24 (12.6) 2 (4.7) 5 (3.5) 1 (2.0) 8 (4.4) 5 (3.0)
Source  of cSSTIc
Community-acquired 749 (49.9) 32 (59.3) 11 (26.8) 122 (46.7) 94 (43.3) 94 (62.3) 74 (38.9) 22 (51.2) 104 (73.8) 4 (8.0) 110 (60.1) 81 (47.9)
Healthcare-associated 371 (24.7) 10 (18.5) 17 (41.5) 82 (31.4) 69 (31.8) 41 (27.2) 31 (16.3) 7 (16.3) 21 (14.9) 10 (20.0) 44 (24.0) 39 (23.1)
Hospital-acquired 81 (5.4) 2 (3.7) 4 (9.8) 4 (1.5) 11 (5.1) 8 (5.3) 3 (1.6) 2 (4.7) 11 (7.8) 3 (6.0) 22 (12.0) 10 (5.9)
Unknown/not documented 301 (20.0) 10 (18.5) 9 (22.0) 53 (20.3) 43 (19.8) 8 (5.3) 82 (43.2) 12 (27.9) 5 (3.5) 33 (66.0) 7 (3.8) 39 (23.1)
Surgical procedures related to cSSTI treatmentd 582 (38.7) 18 (33.3) 20 (48.8) 85 (32.6) 101 (46.5) 67 (44.4) 37 (19.5) 26 (60.5) 88 (62.4) 27 (54.0) 73 (39.9) 40 (23.7)
Incision/drainagee 340 (58.4) 7 (38.9) 12 (60.0) 71 (83.5) 51 (50.5) 27 (40.3) 24 (64.9) 15 (57.7) 59 (67.0) 14 (51.9) 35 (47.9) 25 (62.5)
Amputatione 22 (3.8) 0 1 (5.0) 2 (2.4) 9 (8.9) 1 (1.5) 0 0 4 (4.5) 1 (3.7) 4 (5.5) 0
Debridemente 277 (47.6) 10 (55.6) 11 (55.0) 16 (18.8) 53 (52.5) 50 (74.6) 12 (32.4) 22 (84.6) 33 (37.5) 10 (37.0) 45 (61.6) 15 (37.5)
Othere 19 (3.3) 3 (16.7) 0 2 (2.4) 6 (5.9) 0 1 (2.7) 0 1 (1.1) 3 (11.1) 3 (4.1) 0
Sepsis/septic shock during cSSTI episodef 258 (17.2) 8 (14.8) 7 (17.1) 58 (22.2) 40 (18.4) 25 (16.6) 11 (5.8) 5 (11.6) 46 (32.6) 2 (4.0) 28 (15.3) 28 (16.6)
Infections during hospitalisation
I.v. line infection 33 (2.2) 2 (3.7) 1 (2.4) 3 (1.1) 4 (1.8) 9 (6.0) 0 4 (9.3) 4 (2.8) 0 1 (0.5) 5 (3.0)
Superinfection 84 (5.6) 4 (7.4) 1 (2.4) 13 (5.0) 12 (5.5) 6 (4.0) 3 (1.6) 7 (16.3) 23 (16.3) 3 (6.0) 7 (3.8) 5 (3.0)
S.D., standard deviation; PVD, peripheral vascular disease; CPD, chronic pulmonary disease; CHF, congestive heart failure; CAD, coronary artery disease; MI, myocardial infarction; CABG, coronary artery bypass graft; cSSTI,
complicated skin and soft-tissue infection; i.v., intravenous.
a All countries (N = 1502) includes 2 patients from Ireland; however, data from Ireland were not reported separately owing to the small sample size.
b Patients could have more than 1 co-morbidity; country-speciﬁc data for the top seven co-morbidities overall are presented.
c Healthcare-associated: hospitalisation in past 90 days, residence in nursing home or extended care facility, treatment with chronic haemodialysis, or receipt of home healthcare or wound care; hospital-acquired: >48 h after
hospital  admission.
d Patients could have more than one surgical procedure.
e Percentages calculated from a denominator of ‘surgical procedures related to cSSTI treatment’.
f Severe sepsis/septic shock at any time during the hospital stay.
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Table 2
Percentage of hospitals with antibiotic subcommittees and early switch and early discharge (ED) protocols.
Antibiotic subcommittee or
steering committee (%)
I.v.-to-oral antibiotic
switch protocol (%)
ED protocol for MRSA
cSSTI (oral or OPAT) (%)
All hospitals (N = 341)a 82.9 23.7 12.9
Austria (n = 24) 87.5 4.1 4.1
Czech Republic (n = 10) 80.0 10.0 0
France (n = 48) 91.6 20.8 4.1
Germany (n = 50) 66.0 18.0 12.0
Greece (n = 33) 96.9 12.1 9.0
Italy  (n = 39) 43.5 12.8 7.6
Poland (n = 19) 94.7 47.3 5.2
Portugal (n = 20) 85.0 0 25.0
Slovakia (n = 7) 100.0 71.4 14.2
Spain  (n = 32) 96.8 37.5 28.1
UK  (n = 58) 93.1 43.1 22.4
I.v., intravenous; MRSA, meticillin-resistant Staphylococcus aureus; cSSTI, complicated skin and soft-tissue infection; OPAT, outpatient parenteral antibiotic therapy.
a All hospitals (N = 341) includes 1 location in Ireland; however, data from Ireland were not reported separately owing to the small sample size.
Fig. 1. Observed intravenous (i.v.) days and length of stay (LoS) from complicated skin and soft-tissue infection index date. * The number of early switch (ES)- and early
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Eischarge (ED)-eligible patients is a subset of the sample sizes listed by country. Al
ot  reported separately owing to the small sample size.
.5. Potential opportunities for early switch and early discharge
nd potential savings in intravenous days, hospital length of stay
nd costs
All countries exhibited potential opportunities for ES or ED com-
ared with observed actual treatment patterns. The proportion of
atients meeting key ES criteria varied across countries (range: Slo-
akia, 12.0% to Greece, 56.3%) (Table 4). Among ES-eligible patients,
ean actual i.v. days ranged from 11.3 ± 6.2 days (UK) to 21.5 ± 9.4
ays (Poland) (Fig. 1); following ES criteria could result in potential
.v. line-days saved (mean ± S.D. range: Slovakia, 2.7 ± 1.9 days to
pain, 7.2 ± 8.5 days) (Table 4). The proportion of patients meeting
ey ED criteria varied across countries, ranging from 10.0% (Slo-
akia) to 48.2% (Portugal) (Table 4). Among ED-eligible patients,
verage actual LoS ranged from 14.6 ± 8.8 days (UK) to 28.0 ± 9.4
ays (Poland) (Fig. 1); following ED criteria could result in poten-
ial bed-days saved (mean ± S.D. range: Slovakia, 1.2 ± 0.4 days to
rance, 7.8 ± 10.6 days) (Table 4). Potential cost savings per patient
eeting ED criteria ranged from an estimated D414 (Slovakia) to
2703 (France) when applying the cross-country average cost per
ed-day of D344.87 to all patients (Table 4).. Discussion
This study may  provide the ﬁrst published data on pan-
uropean real-world hospital protocols and treatment patterns fortries (N = 1502) includes 2 patients from Ireland; however, data from Ireland were
MRSA cSSTI with ca. 1500 patients hospitalised in 12 European
countries. Overall, i.v. vancomycin was  the most common initial
treatment for MRSA cSSTI in most countries evaluated; oral line-
zolid was the drug of choice for MRSA cSSTI at hospital discharge.
The majority of patients in all countries were treated only with i.v.
therapy, with ca. 10% of patients switched from i.v. to oral antibiotic
therapy while hospitalised. There were moderate to strong correla-
tions between the country-level proportion of sites with antibiotic
subcommittees and i.v.-to-oral antibiotic switch and/or ED proto-
cols and the proportion of patients with an i.v.-to-oral antibiotic
switch, suggesting that the presence of structures to support stew-
ardship activity may  be drivers for more ES and potentially ED.
However, this may  depend on the actual implementation of these
protocols, which was not captured by this study; we  could not
determine the level of clinician awareness regarding such activity.
Overall, these results show substantial opportunities to decrease
i.v. antibiotic treatment days and hospital LoS by switching patients
from i.v. to oral antibiotic therapy.
The variability in treatment administration patterns and hos-
pital LoS observed across countries may  be due to a number
of reasons, including differences in physician and patient expec-
tations and different healthcare systems among the countries
evaluated [17]. For example, i.v.-to-oral antibiotic switch rate vari-
ability may  be affected by different perceptions on whether oral
antibiotics represent the standard of care for treating serious infec-
tions [18,19]. These perceptions may  partly explain the noted
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Table 3
Country-speciﬁc antibiotic treatment patterns.
All countries
(N = 1502)a
Austria
(n = 54)
Czech
Republic
(n = 41)
France
(n = 261)
Germany
(n= 217)
Greece
(n = 151)
Italy
(n = 190)
Poland
(n = 43)
Portugal
(n = 141)
Slovakia
(n = 50)
Spain
(n = 183)
UK
(n = 169)
MRSA-active therapy [n (%)] 1468 (97.7) 52 (96.3) 40 (97.6) 258 (98.9) 215 (99.1) 149 (98.7) 187 (98.4) 38 (88.4) 139 (98.6) 40 (80.0) 179 (97.8) 169 (100.0)
I.v.-to-oral switch 161 (10.7) 2 (3.7) 3 (7.3) 46 (17.6) 14 (6.5) 3 (2.0) 9 (4.7) 2 (4.7) 8 (5.7) 10 (20.0) 37 (20.2) 27 (16.0)
I.v.  only 1224 (81.5) 46 (85.2) 28 (68.3) 189 (72.4) 192 (88.5) 141 (93.4) 168 (88.4) 36 (83.7) 126 (89.4) 30 (60.0) 138 (75.4) 128 (75.7)
Oral  only 12 (0.8) 1 (1.9) 1 (2.4) 3 (1.1) 1 (0.5) 0 0 0 0 1 (2.0) 4 (2.2) 1 (0.6)
I.v.  and oral inpatient 49 (3.3) 4 (7.4) 8 (19.5) 13 (5.0) 6 (2.8) 1 (0.7) 2 (1.1) 0 0 0 2 (1.1) 13 (7.7)
OPAT  at discharge 34 (2.3) 0 1 (2.4) 10 (3.8) 3 (1.4) 4 (2.6) 8 (4.2) 0 5 (3.5) 0 2 (1.1) 1 (0.6)
Initial  MRSA therapy among patients with MRSA-active therapy [n (%)]b,c
Vancomycin 737 (50.2) 12 (23.1) 21 (52.5) 162 (62.8) 115 (53.5) 43 (28.9) 78 (41.7) 17 (44.7) 97 (69.8) 14 (35.0) 87 (48.6) 90 (53.3)
Linezolid 222 (15.1) 10 (19.2) 3 (7.5) 49 (19.0) 22 (10.2) 31 (20.8) 24 (12.8) 1 (2.6) 28 (20.1) 0 43 (24.0) 11 (6.5)
Clindamycin 159 (10.8) 9 (17.3) 6 (15.0) 13 (5.0) 34 (15.8) 35 (23.5) 10 (5.3) 9 (23.7) 4 (2.9) 8 (20.0) 19 (10.6) 12 (7.1)
Teicoplanin 153 (10.4) 4 (7.7) 1 (2.5) 21 (8.1) 8 (3.7) 19 (12.8) 43 (23.0) 0 1 (0.7) 0 7 (3.9) 48 (28.4)
Fluoroquinolonesd 106 (7.2) 2 (3.8) 1 (2.5) 23 (8.9) 17 (7.9) 20 (13.4) 10 (5.3) 6 (15.8) 1 (0.7) 13 (32.5) 9 (5.0) 4 (2.4)
Daptomycin 87 (5.9) 6 (11.5) 0 4 (1.6) 11 (5.1) 22 (14.8) 20 (10.7) 0 0 1 (2.5) 14 (7.8) 9 (5.3)
Rifampicin 62 (4.2) 2 (3.8) 6 (15.0) 32 (12.4) 10 (4.7) 1 (0.7) 4 (2.1) 0 0 0 1 (0.6) 6 (3.6)
Tigecycline 48 (3.3) 9 (17.3) 0 3 (1.2) 11 (5.1) 5 (3.4) 10 (5.3) 0 2 (1.4) 0 7 (3.9) 1 (0.6)
SXT  45 (3.1) 0 10 (25.0) 5 (1.9) 5 (2.3) 0 1 (0.5) 6 (15.8) 10 (7.2) 3 (7.5) 5 (2.8) 0
Othere 44 (3.0) 3 (5.8) 0 15 (5.8) 5 (2.3) 4 (2.7) 1 (0.5) 2 (5.3) 0 1 (2.5) 1 (0.6) 12 (7.1)
Last  MRSA therapy among patients with MRSA-active therapy [n (%)]b,c
Vancomycin 609 (41.5) 11 (21.2) 21 (52.5) 127 (49.2) 96 (44.7) 41 (27.5) 71 (38.0) 18 (47.4) 82 (59.0) 10 (25.0) 59 (33.0) 72 (42.6)
Linezolid 310 (21.1) 10 (19.2) 4 (10.0) 73 (28.3) 42 (19.5) 41 (27.5) 27 (14.4) 2 (5.3) 33 (23.7) 1 (2.5) 54 (30.2) 23 (13.6)
Teicoplanin 158 (10.8) 4 (7.7) 1 (2.5) 23 (8.9) 13 (6.0) 18 (12.1) 44 (23.5) 0 5 (3.6) 0 6 (3.4) 43 (25.4)
Clindamycin 141 (9.6) 9 (17.3) 5 (12.5) 18 (7.0) 26 (12.1) 21 (14.1) 10 (5.3) 7 (18.4) 2 (1.4) 7 (17.5) 23 (12.8) 13 (7.7)
Fluoroquinolonesd 110 (7.5) 2 (3.8) 0 27 (10.5) 13 (6.0) 16 (10.7) 10 (5.3) 6 (15.8) 2 (1.4) 18 (45.0) 14 (7.8) 2 (1.2)
Daptomycin 98 (6.7) 6 (11.5) 0 6 (2.3) 17 (7.9) 24 (16.1) 22 (11.8) 0 1 (0.7) 1 (2.5) 13 (7.3) 8 (4.7)
Rifampicin 60 (4.1) 2 (3.8) 5 (12.5) 30 (11.6) 8 (3.7) 1 (0.7) 4 (2.1) 0 0 0 5 (2.8) 5 (3.0)
SXT  56 (3.8) 0 9 (22.5) 6 (2.3) 5 (2.3) 0 4 (2.1) 8 (21.1) 10 (7.2) 2 (5.0) 12 (6.7) 0
Tigecycline 54 (3.7) 10 (19.2) 0 2 (0.8) 10 (4.7) 7 (4.7) 10 (5.3) 0 4 (2.9) 0 10 (5.6) 1 (0.6)
Otherse 58 (4.0) 3 (5.8) 0 11 (4.3) 6 (2.8) 4 (2.7) 1 (0.5) 1 (2.6) 6 (4.3) 1 (2.5) 1 (0.6) 24 (14.2)
Discharge MRSA therapy [n (%)] 480 (32.7) 15 (28.8) 9 (22.5) 107 (41.5) 51 (23.7) 74 (49.7) 40 (21.4) 10 (26.3) 25 (18.0) 14 (35.0) 80 (44.7) 54 (32.0)
OPATf 35 (7.3) 0 1 (11.1) 10 (9.3) 3 (5.9) 5 (6.8) 8 (20.0) 0 5 (20.0) 0 2 (2.5) 1 (1.9)
Oralf 445 (92.7) 15 (100.0) 8 (88.9) 97 (90.7) 48 (94.1) 69 (93.2) 32 (80.0) 10 (100.0) 20 (80.0) 14 (100.0) 78 (97.5) 53 (98.1)
Discharge therapy [n (%)]
Linezolidf 202 (42.1) 5 (33.3) 2 (22.2) 56 (52.3) 26 (51.0) 29 (39.2) 8 (20.0) 0 13 (52.0) 0 43 (53.8) 20 (37.0)
Clindamycinf 95 (19.8) 6 (40.0) 3 (33.3) 8 (7.5) 15 (29.4) 21 (28.4) 10 (25.0) 2 (20.0) 0 2 (14.3) 14 (17.5) 13 (24.1)
Fluoroquinolonesd,f 67 (14.0) 1 (6.7) 0 11 (10.3) 5 (9.8) 19 (25.7) 7 (17.5) 4 (40.0) 1 (4.0) 9 (64.3) 10 (12.5) 0
SXTf 57 (11.9) 0 3 (33.3) 11 (10.3) 2 (3.9) 7 (9.5) 7 (17.5) 4 (40.0) 5 (20.0) 1 (7.1) 16 (20.0) 0
Rifampicinf 34 (7.1) 1 (6.7) 0 10 (9.3) 2 (3.9) 6 (8.1) 3 (7.5) 0 0 0 8 (10.0) 4 (7.4)
Teicoplaninf 14 (2.9) 0 0 4 (3.7) 0 1 (1.4) 8 (20.0) 0 0 0 0 1 (1.9)
Vancomycinf 11 (2.3) 0 0 4 (3.7) 1 (2.0) 1 (1.4) 0 0 5 (20.0) 0 0 0
Tigecyclinef 2 (0.4) 0 0 0 0 0 0 0 0 0 0 0
Daptomycinf 1 (0.2) 0 0 1 (0.9) 0 0 0 0 0 0 0 0
Othere,f 54 (11.3) 3 (20.0) 0 13 (12.1) 1 (2.0) 7 (9.5) 2 (5.0) 0 1 (4.0) 2 (14.3) 2 (2.5) 23 (42.6)
MRSA, meticillin-resistant Staphylococcus aureus; i.v., intravenous; OPAT, outpatient parenteral antibiotic therapy; SXT, trimethoprim/sulfamethoxazole.
a All countries (N = 1502) includes 2 patients from Ireland; however, data from Ireland were not reported separately owing to the small sample size.
b Drug groups are not mutually exclusive; multiple medications could be used simultaneously.
c Percentages calculated from a denominator based on number of patients with ‘MRSA-active therapy’.
d Fluoroquinolones included ciproﬂoxacin, levoﬂoxacin, moxiﬂoxacin, norﬂoxacin and oﬂoxacin.
e Other antibiotics included doxycycline, ertapenem, fusidic acid, gentamicin, imipenem, meropenem, minocycline, pristinamycin, quinupristin/dalfopristin and trimethoprim.
f Percentages calculated from a denominator based on number of patients from ‘discharge MRSA therapy’.
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practice variations despite the availability of modern oral formu-
lations that are highly bioavailable with good safety proﬁles [17]
and equivalent effectiveness [20,21]. Moreover, oral MRSA-active
drugs have been implemented in recent algorithms and guide-
lines for treatment of MRSA cSSTI, further supporting the use of
these agents [22–24]. The extent and severity of the infections
may  have contributed to reluctance to switch patients from i.v.
to oral formulations or to discharge patients sooner. Of note, in
the current patient population, 17.2% of patients developed severe
sepsis/septic shock at any time during the hospital stay, and ca. 70%
had more complicated infections such as deep cellulitis, abscess or
ulcer. This is higher than the 4–6% of patients with sepsis in trials of
antibiotic treatment of cSSTI with or without microbiological evi-
dence of MRSA [21,25]. In addition, patients in this real-world study
were older and had more baseline co-morbidities compared with
typical clinical trial populations [26]. Although we were unable to
assess extent and severity using lesion size in this retrospective
study, as is done in a clinical trial, the current population were all
MRSA-conﬁrmed cSSTI, which is considered a more severe popu-
lation than more recent trials assessing the broader indication of
acute bacterial skin and skin-structure infections with only MRSA
subpopulations present [26].
One strength of this data set is that it was  collected in a consis-
tent manner across countries, which makes it possible to evaluate
differences throughout Europe. However, we accept that the case-
mix  in the different hospital populations was not uniform and may
make benchmarking difﬁcult. This study ﬁlls a gap in the litera-
ture by providing practice pattern data for each country included
together with patient clinical and demographic characteristics. In
addition, differences in living conditions, infrastructure of out-
patient treatment, usual treatment behaviours and culture, and
healthcare system economics may  also contribute to the observed
differences across countries. Incentives and barriers for discharge
and reimbursement are likely signiﬁcant drivers for the differences
observed.
In comparison with the typical real-world US LoS for cSSTI of ca.
5 days [27] where there are strong incentives to minimise hospital
days, the typical LoS in this observational European study was  ca.
20 days in an MRSA-speciﬁc population. These differences in LoS by
region have also been conﬁrmed in a phase 4 MRSA cSSTI clinical
trial [13], with the USA having a LoS of ca. 4–5 days while Europe
had a LoS of ca. 13–15 days. The long LoS in the current study may
have resulted in the low 30-day post-discharge recurrence (<1%)
and re-admission (<1%) rates due to MRSA cSSTI, coupled with the
potential limitation in follow-up data availability if patients were
re-admitted to a different hospital. In the USA, 30-day re-admission
rates for cSSTI are signiﬁcant at 7–13% for cSSTI in retrospective
observational analyses [28].
Limitations of this study include the retrospective observational
design in the calculation of potential country cost savings with
application to ES and ED criteria. To verify the ﬁndings, a prospec-
tive trial should test the effect of implementing deﬁned ES and
ED criteria, or a controlled cohort study could compare the same
hospitals before and after the implementation of such criteria.
However, such studies may  not be practical or economical given
the complexities of such a multinational study. For this reason,
the most pragmatic method to capture current practice patterns
across many countries was likely a retrospective design to avoid
bias in physician behaviours (Hawthorne effect) when prospective
data collection was occurring. Despite these limitations, real-world
data are increasingly recognised as a critical piece of information
in healthcare decision-making, particularly when evaluating prac-
tical aspects of implementing ES and ED protocols and systems that
are functional and easy to use.
In this study, countries did not contribute data equally [ca.
70% of patients came from 5 Western European countries (France,
al of A
G
t
M
f
i
w
i
E
r
i
d
>
f
c
s
s
c
v
s
m
i
p
e
M
m
E
a
i
w
t
d
A
c
p
a
b
P
a
i
L
S
W
D
M
f
A
f
b
h
f
a
t
M
f
I
t
o
e
[
[
[
[
[
[
[
[
[
[
[
[
[
[C. Eckmann et al. / International Journ
ermany, Italy, Spain and the UK)]. However, this data collec-
ion pattern may  actually reﬂect the epidemiology and burden of
RSA cSSTI across Europe. The countries that contributed data on
ewer patients (e.g. Austria, Slovakia, Poland and Czech Republic)
ndicated having fewer MRSA cSSTI cases to screen for inclusion,
hich was consistent with their published epidemiology report-
ng MRSA rates of 7–14%. In contrast, MRSA rates in the 5 Western
uropean countries heavily represented in this study have been
eported to be ≥25% [25], and these 5 European countries exhib-
ted some of the most signiﬁcant opportunities to reduce i.v. line
ays and hospital LoS and achieve potential savings of D1500 to
D2400 per ED-eligible patient. Interestingly, in other countries, we
ound the highest opportunity for ED (41% of patients with MRSA
SSTI in Greece, facing severe economic crisis and austerity mea-
ures, with rates of MRSA of >40% [25]) could have been discharged
ooner using a criteria-based approach with signiﬁcant potential
ost savings (>D2500 per ED-eligible patient). This exempliﬁes the
alue of the country-level data that could, together with local deci-
ion factors, inﬂuence local patterns in allocating limited resources
ost effectively. Whilst this study focused on MRSA cSSTI, a sim-
lar criteria-based approach for other infections or diseases could
rovide opportunities to improve economic outcomes.
In conclusion, this large study is the ﬁrst to document differ-
nces in actual treatment patterns of hospitalised patients with
RSA cSSTI among European countries. Wide variation in treat-
ent patterns and resource utilisation occurred across countries.
vidence supports a correlation between the availability of local
ntibiotic stewardship activity, such as ES and ED protocols, and
ncreased likelihood of reduced hospital LoS. Furthermore, using
ell-accepted ES and ED criteria, signiﬁcant opportunities for cer-
ain patients to be switched from i.v. to oral antibiotic therapy and
ischarged home from the hospital sooner were identiﬁed.
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